These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23075021)

  • 21. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
    Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
    Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ; Karakiewicz P; Bavbek S; Rha SY; Bracarda S; Bahl A; Ou YC; Kim D; Panneerselvam A; Anak O; Grünwald V
    Urology; 2013 Jan; 81(1):143-9. PubMed ID: 23273080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression-free survival as endpoint in metastatic RCC?
    Knox JJ
    Lancet; 2008 Aug; 372(9637):427-9. PubMed ID: 18653227
    [No Abstract]   [Full Text] [Related]  

  • 27. The ORCHIDEE study: gathering new evidence on the use of everolimus in clinical practice.
    Rizzo M; Cartenì G; Pappagallo G; Hollander L; Floriani I
    Tumori; 2014; 100(6):e290-2. PubMed ID: 25688513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 29. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.
    Stein A; Wang W; Carter AA; Chiparus O; Hollaender N; Kim H; Motzer RJ; Sarr C
    BMC Cancer; 2012 Jul; 12():311. PubMed ID: 22824201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.
    Kuru TH; Huber J; Hatiboglu G; Wagener N; Pahernik S; Hadaschik B; Hohenfellner M
    Urol Int; 2011; 86(3):256-60. PubMed ID: 21266794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role of everolimus in inducing cholestasis.
    Pantano F; Santini D; Guida F; Vincenzi B; Tonini G
    Ann Oncol; 2010 Feb; 21(2):433. PubMed ID: 19955336
    [No Abstract]   [Full Text] [Related]  

  • 33. An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
    Wunder C; Kopp-Schneider A; Edler L
    J Biopharm Stat; 2012; 22(2):294-311. PubMed ID: 22251175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 35. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
    Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
    Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method.
    Zhang J; Chen C
    Stat Med; 2016 Sep; 35(21):3690-703. PubMed ID: 26919271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus in advanced or metastatic breast cancer.
    Prescrire Int; 2013 Nov; 22(143):260. PubMed ID: 24427832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching.
    Jiménez JL; Niewczas J; Bore A; Burman CF
    PLoS One; 2021; 16(11):e0259178. PubMed ID: 34780488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use.
    Prasad V; Kim MS; Haslam A
    Trials; 2023 Jun; 24(1):373. PubMed ID: 37270500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.
    Massard C; Fizazi K; Gross-Goupil M; Escudier B
    Invest New Drugs; 2010 Dec; 28(6):879-81. PubMed ID: 19649567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.